What about the acquisition of a marketing and distribution company?
In an interview following the third Phase 2 result, the topic of acquisition was raised by the interviewer. I think it’s in the context of additions to the drug pipeline, but why not bolt on a sales and marketing division and retain all the value of NNZ-2591?
Timestamp: 23:30
On the Couch with Jon Pilcher: What’s Next for Neuren Pharma
A search on Grok suggests there are a few options that could be "affordable" (less than $1B). With successful Phase 3 approvals, we should be worth US$7–10B, so it could be a good investment.
What about the acquisition of a marketing and distribution...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.17 |
Change
-0.370(2.95%) |
Mkt cap ! $1.511B | |||
| Open | High | Low | Value | Volume |
| $12.45 | $12.45 | $11.88 | $3.172M | 262.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 35 | $12.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.19 | 334 | 4 |
View Market Depth
| Last trade - 12.31pm 23/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |